Thousand Oaks-based biotechnology company, Amgen found from a Phase 2 study that their drug, Aranesp, used to treat patients with symptomatic heart failure and anemia, was well tolerated...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 26 biweekly issues
  • Subscriber-only digital content for prime stories
  • Book of Lists — the most comprehensive business resource in the Valley region
Yours for only $49